News | October 19, 2012

DESolve I First-In-Man Study Positive for the Fully Bioresorbable Drug-Eluting Coronary Stent

Data shows low late-lumen loss, zero percent binary restenosis and low neo-intimal volume obstruction

DESolve Bioresorbable Coronary Scaffold System Clinical Trial

October 19, 2012 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced six-month clinical, IVUS (Intravascular Ultrasound), OCT (Optical Coherence Tomography) and angiographic data for its 15-patient First-In-Man clinical study of the fully bioresorbable drug-eluting scaffold, the DESolve Bioresorbable Coronary Scaffold System at a late-breaking trial session of EuroPCR in Paris.

At  six months, Elixir’s DESolve demonstrated excellent late lumen loss of 0.19 ± 0.19 mm, no reblockage of the artery (0.0% binary restenosis), no late malapposition (0.0 percent), low acute recoil (6.4 percent ± 4.3), no cases of blood clots (0.0 percent stent thrombosis) and a single MACE event due to a stenosis in the segment 5 mm proximal to the scaffold, which itself was widely patent. Imaging results also demonstrated low neointimal volume obstruction of 7.1 percent and no late recoil or scaffold shrinkage. OCT, which provides high resolution intravascular imaging, confirmed these results and showed that over 98 percent of the scaffold struts were covered with a thin, uniform neointimal layer (0.12 mm) at six months. The 15 patients were enrolled in Europe and New Zealand, and will continue to be followed-up at subsequent yearly intervals for 5 years.

“Bioresorbable scaffolds that restore the coronary vessel to its normal form and function without leaving a permanent implant in the body have long been considered the ultimate frontier in interventional cardiology,” said Stefan Verheye, M.D., Ph.D., ZNA Middleheim Hospital, Antwerp, Belgium, and principal investigator of the DESolve I Study, who presented the results at a Hot Line session. “Having used the DESolve bioresorbable scaffold system and observed its impressive performance and follow up results, I am confident that Elixir’s DESolve scaffold system has the potential to reduce long-term adverse clinical events, and eliminate the need for long-term dual anti-platelet therapy.”

“Elixir Medical is excited about the potential impact of this revolutionary technology on vascular intervention, and is committed to bringing DESolve to the market through evidence-based clinical research,” said Motasim Sirhan, chief executive officer of Elixir Medical. “In order to provide our physicians with unrivaled treatment options to improve patient outcomes, Elixir has ensured that DESolve will be available in a broad range of sizes, and that our manufacturing capacity is scalable for future studies and commercialization.”

To build upon the results of the DESolve FIM study, Elixir has initiated a pivotal trial, the DESolve Nx, which is currently enrolling 120 patients across Europe, New Zealand and Brazil. This trial will evaluate the safety and efficacy of Elixir’s DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System with the primary safety endpoint being a composite of major adverse cardiac events (MACE). The primary angiographic endpoint of the trial will be in-stent late lumen loss at six months for all patients as assessed by QCA (Quantitative Coronary Angiography).

Bioresorbable scaffold technology had thus far been a challenge in the industry because it required a level of strength and support that only permanent metallic stents had been able to provide, the safe and gradual bioresorption of the strong scaffold once the blood vessel healed and could support itself, and the inclusion of an active pharmaceutical ingredient for its therapeutic, anti-proliferative effect. The DESolve scaffold made from a proprietary and proven poly-L Lactide (PLLA)-based polymer provides optimal strength and support to the artery while delivering an anti-proliferative drug, and is designed to resorb in the body within one to two years.

For more: www.elixirmedical.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Overlay Init